When Cancer Vaccines Go Viral.
David RepárazDiana LlopizPablo SarobePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to patients with cancer. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.See related article by Gatti-Mays et al., p. 4933.